FibroGen has begun enrolling patients in a new Phase II study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of FG-3019 in IPF patients. The primary endpoint of the study is lung function, as measured by change in forced vital capacity (FVC). Secondary endpoints include change in lung fibrosis as measured by quantitative high resolution computed tomography (HRCT) sc...